Everything below concerns lipolysis. We keep the language plain, cite what the science says, and separate well-supported claims from open questions.
Last reviewed on 2025-11-16. Where a claim depends on a specific study, the study is described rather than over-claimed.
Storage claims vary across suppliers, and published stability data for specific formulations are limited. Extrapolating from related peptides is common but not a substitute for direct measurement. For research use, documentation such as a certificate of analysis is often requested to confirm identity and purity. What constitutes an acceptable purity threshold depends on the intended application. Open questions remain about how temperature excursions during shipping affect long-term peptide integrity. Independent verification by an end user is not routinely reported.
Lyophilized tesamorelin is generally stored refrigerated at 2 to 8 degrees Celsius, protected from light and moisture. Peptides in this class are often kept frozen at minus 20 degrees Celsius for longer periods. Reconstituted solutions are typically used within a defined window because hydrolysis and oxidation proceed faster in liquid form. Container material and headspace also influence how long a preparation retains its expected profile. Specific stability figures depend on concentration and buffer composition.
Tesamorelin occupies a narrow position among agents that act on the growth hormone axis. Unlike growth hormone itself, which is given as replacement, it stimulates the pituitary to release the hormone in pulses, so the downstream increase in insulin-like growth factor 1 depends on intact somatotroph function. Other peptides in the same family include shorter GHRH fragments and synthetic secretagogues with different stability profiles. Several points remain unresolved, including whether the reduction in visceral fat translates into fewer cardiovascular events, what happens to metabolic markers after long-term use, and how the drug compares with lifestyle or surgical approaches.
Tesamorelin is a synthetic peptide that belongs to the growth hormone-releasing hormone family and contains the same forty-four amino acid sequence as endogenous GHRH, extended at the amino terminus by a trans-3-hexenoyl group. That small fatty acid modification protects the peptide from rapid cleavage by dipeptidyl peptidase-4, the enzyme that shortens the half-life of native GHRH to only a few minutes. Chemically the compound is produced by solid-phase peptide synthesis, purified by chromatography, and supplied as a sterile lyophilized powder for reconstitution.
| Property | Value | Notes |
|---|---|---|
| Physical form | Lyophilized powder | Requires reconstitution before use |
| Solubility | Soluble in water | Also dissolves in aqueous buffers |
| Storage, powder | 2 to 8 degrees Celsius | Protect from light and moisture |
| Storage, solution | Refrigerated, short term | Use promptly after reconstitution |
| Common assays | Reversed-phase HPLC and mass spectrometry | Purity and identity respectively |
Regulatory position depends on jurisdiction and on the form in which the material is sold. A branded product holds approval in the United States for a defined indication, and prescribing is confined to that label. Material marketed for laboratory research is not evaluated for human use and carries no such clearance. Independent verification therefore rests on certificates of analysis, third-party testing, and documented chain of custody. The substance also appears on the World Anti-Doping Agency prohibited list within the category covering growth hormone-releasing factors.
Lyophilized material is typically held under refrigeration between two and eight degrees Celsius, shielded from light and ambient moisture. Peptides of this size adsorb to glass and plastic, so working procedures often call for low-binding containers and as few transfers as possible. Absorbed water during weighing shifts the apparent mass of a sample, and controlling room humidity reduces that source of error. Once dissolved, solutions are kept cold and used within the interval printed on the accompanying label or certificate. Degradation accelerates markedly in dilute aqueous form.
Identity and purity are judged through a combination of chromatographic and mass spectrometric techniques. Reversed-phase high-performance liquid chromatography separates the intact peptide from truncated, oxidized, and deamidated variants, and the resulting peak-area percentages yield a purity figure. Electrospray ionization mass spectrometry confirms the expected molecular mass and can expose unanticipated modifications. Amino acid analysis and peptide mapping support sequence fidelity, while water content, pH, sterility, and bacterial endotoxin testing describe the physical and microbiological attributes of a finished lot.
研究背景集中在特定人群的体成分改变，尤其是与脂肪分布异常相关的内脏脂肪堆积。不同地区对它的监管状态与获批适应症并不一致，部分市场仅限特定诊断人群使用。在一般人群中的长期效应、与其他激素的相互作用以及停药后的维持情况仍属开放问题，现有数据不足以给出普遍结论。
tesamorelin 是一种人工合成的四十四肽，序列与内源性生长激素释放激素（GHRH）的 1-44 片段一致，区别在于 N 端加接了一个反式-3-己烯酰基。该修饰抑制二肽基肽酶 IV 的快速切割，从而延长分子在循环中的存留时间。作为肽类分子，它难以经胃肠道吸收，文献中讨论的均是注射途径。分类上通常把它归为 GHRH 类似物，以区别于生长激素本身。
作用位置在垂体前叶。tesamorelin 与 GHRH 受体结合后激活腺苷酸环化酶，升高细胞内 cAMP，再经蛋白激酶 A 通路促进生长激素的合成与释放。由于它作用于内源调控节点，生长激素仍以脉冲方式分泌，而不是被持续抬升到固定水平。生长激素随后在肝脏等组织诱导胰岛素样生长因子 1 产生，构成完整的生长激素轴响应。
Pharmacodynamic studies show that tesamorelin reduces visceral adipose tissue more than subcutaneous adipose tissue in the studied population. This selectivity may relate to differences in blood flow and hormone sensitivity between fat depots. Effects on glucose metabolism and insulin sensitivity have been investigated, with some trials reporting modest changes and others showing stability. The precise relationship between growth hormone exposure, IGF-1 levels, and visceral fat loss remains an active area of analysis.
Tesamorelin binds to growth hormone-releasing hormone receptors on somatotroph cells in the anterior pituitary. Receptor activation increases intracellular cyclic AMP and promotes synthesis and secretion of growth hormone. Because the peptide mimics endogenous GHRH, it amplifies the normal pulsatile release of growth hormone rather than providing exogenous growth hormone directly. This upstream action distinguishes tesamorelin from recombinant growth hormone preparations and from growth hormone secretagogues that act at different receptors.
Stimulated growth hormone release leads to hepatic production of insulin-like growth factor 1, a key mediator of many growth hormone effects. In clinical studies, tesamorelin increased IGF-1 levels in a dose-dependent manner, although the response varies among individuals. The drug's effect on visceral fat is thought to involve growth hormone-mediated lipolysis and altered adipocyte metabolism. Muscle mass and lean body mass have also been assessed as secondary outcomes, but changes are generally smaller and less consistent than fat reductions.
Tesamorelin binds to growth hormone-releasing hormone receptors on the surface of pituitary somatotroph cells. This binding activates adenylate cyclase, raising intracellular cyclic AMP levels and triggering the release of growth hormone into circulation. The elevated growth hormone then stimulates hepatic production of insulin-like growth factor 1. Because the effect is mediated through the endogenous axis, secretion remains subject to feedback regulation. This distinguishes it from direct growth hormone administration, which bypasses pituitary control entirely.
Clinical investigation has focused on HIV-associated lipodystrophy, a condition in which antiretroviral therapy contributes to abnormal fat distribution. Excess visceral adipose tissue accumulates in the abdomen while peripheral fat may be lost. Tesamorelin was evaluated for reducing this visceral fat depot, with trials measuring changes in abdominal fat by imaging rather than by body weight alone. The rationale rests on the known lipolytic effects of growth hormone. Effects on visceral fat are documented, while long-term outcomes regarding cardiovascular risk remain less clearly established.
Tesamorelin is a synthetic peptide analog of growth hormone-releasing hormone, composed of 44 amino acids. It was designed to retain the biological activity of the native hormone while resisting rapid enzymatic degradation. The compound is classified as a growth hormone secretagogue and belongs to the broader family of hypothalamic releasing factors. In research and clinical settings, it is studied for its ability to stimulate pituitary growth hormone release. Its structure includes a modification at the N-terminus that contributes to an extended half-life relative to native growth hormone-releasing hormone.
=== Clinical and translational applications === Much of this methodological work feeds directly into clinical practice: Borchers' laboratory has applied targeted mass spectrometry to cancer biomarkers and precision oncology, and to other clinical questions, including a 2024 study characterizing the proteomic changes from acute to post-acute (long) COVID-19. His group has also investigated targeted proteomics for anti-doping applications, including a project funded by the Partnership for Clean Competition that used longitudinal blood-protein profiling to screen for blood doping. From 2012 he was one of three project leaders, with Andrew Penn and Shelagh Coutts, on a $9.6 million Genome Canada large-scale applied research project that sought to develop a rapid, inexpensive blood test to distinguish transient ischaemic attacks from conditions that mimic them and reduce reliance on neuroimaging. The project produced an electronic triage tool that came into clinical use on Vancouver Island, alongside work on candidate protein biomarkers.
A 2017 film adaptation of Wonder, starring Julia Roberts, Owen Wilson and Jacob Tremblay, was released in November 2017. A stage adaption premiered in 2025, with actor Garrett McNally, who has Treacher Collins syndrome himself, portraying the character in certain shows. Alison Midstokke, who appears in the drama film Happy Face (2018), is an actress and activist who has the condition.
==== Entrapment of catalytically active noble metal nanoparticles ==== The entrapment of catalytically active noble metals can be accomplished by grafting on functional groups to the unsaturated metal site on MOFs. Ethylenediamine (ED) has been shown to be grafted on the Cr metal sites and can be further modified to encapsulate noble metals such as Pd. The entrapped Pd has similar catalytic activity as Pd/C in the Heck reaction. Ruthenium nanoparticles have catalytic activity in a number of reactions when entrapped in the MOF-5 framework. This Ru-encapsulated MOF catalyzes oxidation of benzyl alcohol to benzaldehyde, although degradation of the MOF occurs. The same catalyst was used in the hydrogenation of benzene to cyclohexane. In another example, Pd nanoparticles embedded within defective HKUST-1 framework enable the generation of tunable Lewis basic sites. Therefore, this multifunctional Pd/MOF composite is able to perform stepwise benzyl alcohol oxidation and Knoevenagel condensation.
== Example values == A PDCAAS value of 1 is the highest, and 0 the lowest. The table shows the ratings of selected foods. Parenthesized values reflect the value without truncation. A few more values can be found in Boye et al. 2012. Note the use of several different scoring profiles in this work: "updated" versions of PDCAAS may use profiles different from the 1993 original.
== Further reading == Bryant, Alfred T. (1964). A History of the Zulu and Neighbouring Tribes. Cape Town: C. Struik. p. 157. Cana, Frank Richardson (1911). "Zululand" . Encyclopædia Britannica. Vol. 28 (11th ed.). pp. 1050–1055.
Sources: en.wikipedia.org
=== Metabolism === Ibutilide has a high systemic plasma clearance that closes to the hepatic blood flow (29mL/min/kg). Its metabolic pathway is via liver's cytochrome P450 system by isoenzymes other than CYP3A4 and CYP2D6 by which the heptyl side chain of ibutilide is oxidized. With eight metabolites are detected in the urine, however, only one is an active metabolite that shares the similar electrophysiologic property of the Class III antiarrhythmic agents. The plasma concentration of this metabolite is only less than 10% of ibutilide.
The 1st Special Forces Group is responsible for operations in the Pacific. Currently, the First Battalion is stationed at Okinawa while the 2nd, 3rd, 4th, and Group Support Battalions are stationed at Joint Base Lewis-McChord, Washington. 1st Special Forces Group's history began at Fort Bragg, NC, in 1955. Four Special Forces Operational Detachments - the 12th, 13th, 14th, and 16th - were selected from the 77th Special Forces Group and transferred to the Pacific theater over the next year. 1st Special Forces Group was officially activated at Fort Buckner, Okinawa, on 24 June 1957, with LTC A. Scott Madding as commander and MSG Robert L. Voss as the sergeant major. The 1st Special Forces Group holds the distinction of having the first and last Special Forces soldiers killed in Vietnam: Captain Harry Cramer killed 21 October 1957, and Captain Richard M. Rees killed 15 December 1973. Decades later, another 1st Special Forces Group soldier became the first American to die by hostile fire in Afghanistan: Sergeant First Class Nathan Chapman killed 2 January 2002. The 1st Special Forces Group on Okinawa was one of two Special Action Forces/Security Assistance Forces (SAF) built around Special Forces Groups. The other was built around the 8th Special Forces Group in Panama. SAF Asia was flexible and 1st Group could task organize a detachment for any time of mission in the Pacific rim. During the Vietnam War, it sent teams to Vietnam for six-month temporary duty.
Escherichia coli infections, Klebsiella aerogenes infections, Shigella species infections, Acinetobacter species infections, respiratory tract infections caused by Haemophilus influenzae, respiratory tract and urinary tract infections caused by Klebsiella species.
Coaxil (BG, CR, CZ, EE, HU, LT, LV, PL, RO, RU, SK UA) Salymbra (EE) Stablon (AR, AT, BR, FR, HK, IN, ID, MY, MX, PK, PT, SG, SK, TH, TT, TR, VE) Tatinol (CN) Tianeurax (DE) Tynept (IN) Zinosal (ES) Tianesal (PL)
=== 1945–1979: Post-war Japan and diversification === After World War II, Ajinomoto was slow to resume production of its seasoning as it lacked sufficient funds to continue production and its factory had been destroyed. In April 1946, the company changed its name to Ajinomoto Co., Ltd. In 1947 production of the seasoning resumed, in addition to the production of new food products such as nucleic acid-based seasonings and processed foods. In May 1949 Ajinomoto was listed on the Japanese stock exchange. By 1950, exports accounted for 95% of the company's revenue, with exports to Southeast Asia, Europe, and the United States increasing in subsequent years. In Europe, AJI-NO-MOTO was used as a seasoning by many processed food manufacturers, including Maggi and C.H. Knorr AG. In 1950, sales in Japan resumed after the lifting of postwar sales controls, surpassing pre-war sales by 1953.
Sources: en.wikipedia.org
=== Argentation chromatography === Ag+ binds alkenes reversibly, and silver nitrate has been used to separate mixtures of alkenes by selective absorption. This phenomenon is the basis of argentation chromatography. In some cases, alkene complexes can be isolated. The alkene can be liberated with ammonia.
Bird collections are used for a wide variety of purposes. All biological species including those of birds are represented by a holotype, the vast majority of which are full specimens (mostly skins) and in modern times explicitly designated in the original description of the taxon. All other putative members of the species may be compared to the holotype to confirm their identification. Rigorous studies of avian taxonomy are based on specimens from bird collections. Taxonomic studies rely on morphological and genetic characters to determine species limits and evolutionary relationships. Museum specimens have been the preferred source for scoring these characteristics, as they allow studies to be replicated – anyone may go back and repeat the study using the same specimens to verify the conclusions. However, it has alternatively been argued that such re-examination can be undertaken from archived photographs without killing the study piece.
Mestanolone, also known as methylandrostanolone and sold under the brand names Androstalone and Ermalone among others, is an androgen and anabolic steroid (AAS) medication which is mostly no longer used. It is still available for use in Japan however. It is taken by mouth. Side effects of mestanolone include symptoms of masculinization like acne, increased hair growth, voice changes, and increased sexual desire. It can also cause liver damage. The drug is a synthetic androgen and anabolic steroid and hence is an agonist of the androgen receptor (AR), the biological target of androgens like testosterone and dihydrotestosterone (DHT). It has strong androgenic effects and weak anabolic effects, which make it useful for producing masculine psychological and behavioral effects. The drug has no estrogenic effects. Mestanolone was discovered in 1935 and was introduced for medical use in the 1950s. In addition to its medical use, mestanolone has been used to improve physique and performance. It was used in East Germany in Olympic athletes as part of a state-sponsored doping program in the 1970s and 1980s. The drug is a controlled substance in many countries and so non-medical use is generally illicit.
=== Iraq === In a March 2000 article in The Guardian, Galloway described himself as a supporter of the Iraqi people and the Ba'ath Party, but not Saddam Hussein himself. In a House of Commons debate on 6 March 2002, Foreign Office minister Ben Bradshaw said Galloway was "not just an apologist, but a mouthpiece, for the Iraqi regime over many years." Galloway called the minister a liar and refused to withdraw on the grounds that Bradshaw's claim was "a clear imputation of dishonour", and the sitting was suspended due to the dispute. Bradshaw later withdrew his allegation, and Galloway apologised for using unparliamentary language. Giving evidence in his libel case against The Daily Telegraph in 2004, Galloway testified that he regarded Saddam as a "bestial dictator" and would have welcomed his removal from power, but not by means of a military attack on Iraq. Galloway also pointed out that he was a prominent critic of Saddam Hussein's government in the 1980s, as well as of the role of Margaret Thatcher's government in supporting arms sales to Iraq during the Iran–Iraq War.
They are cigar-shaped but slightly broader at the "front" end, which is the aboral, vegetal-pole end and eventually attaches to a substrate if the species has a polyp stage. Anthozoan larvae either have large yolks or are capable of feeding on plankton, and some already have endosymbiotic algae that help to feed them. Since the parents are immobile, these feeding capabilities extend the larvae's range and avoid overcrowding of sites. Scyphozoan and hydrozoan larvae have little yolk and most lack endosymbiotic algae, and therefore have to settle quickly and metamorphose into polyps. Instead, these species rely on their medusae to extend their ranges.
Sources: en.wikipedia.org
Refrigeration between 2 and 8 degrees Celsius with protection from light is the common recommendation. Many laboratories choose frozen storage at minus 20 degrees Celsius when the material will not be used soon. Repeated temperature cycling is generally avoided.
Mass spectrometry gives the observed mass, which is compared against the value calculated from the sequence. Peptide mapping after digestion provides a second, sequence-level check. Chromatographic retention alone is not sufficient for identity.
Antibodies raised against one GHRH-related peptide may bind other members of the same family. That cross-reactivity inflates or distorts measured concentrations. Assay validation with defined standards is therefore necessary before results are interpreted.
It is a laboratory-made peptide of forty-four amino acids whose sequence matches human growth hormone-releasing hormone, with a modified amino terminus. The modification is a short unsaturated fatty acid chain attached to the first residue. This change slows enzymatic breakdown and lengthens the time the peptide stays active in circulation.